Neuronal Ceroid Lipofuscinosis: A Common Pathway?
暂无分享,去创建一个
[1] D. Pearce,et al. The neuronal ceroid lipofuscinoses , 2007, NeuroMolecular Medicine.
[2] M. Hermansson,et al. Mass spectrometric analysis reveals changes in phospholipid, neutral sphingolipid and sulfatide molecular species in progressive epilepsy with mental retardation, EPMR, brain: a case study , 2005, Journal of neurochemistry.
[3] A. VanDongen,et al. A Galactosylceramide Binding Domain Is Involved in Trafficking of CLN3 from Golgi to Rafts via Recycling Endosomes , 2004, Pediatric Research.
[4] A. Hoogeveen,et al. The MTG proteins: chromatin repression players with a passion for networking. , 2004, Genomics.
[5] P. Filipek,et al. Seizures, depression and dementia in teenagers with Batten disease , 1993, Journal of Inherited Metabolic Disease.
[6] A. VanDongen,et al. Motifs within the CLN3 protein: modulation of cell growth rates and apoptosis. , 2002, Human molecular genetics.
[7] L. Peltonen,et al. Neuronal ceroid lipofuscinoses are connected at molecular level: interaction of CLN5 protein with CLN2 and CLN3. , 2002, Molecular biology of the cell.
[8] A. Amalfitano,et al. The CLN3 gene is a novel molecular target for cancer drug discovery. , 2002, Cancer research.
[9] D. Pearce,et al. The neuronal ceroid lipofuscinoses: mutations in different proteins result in similar disease. , 2002, Neuromolecular medicine.
[10] T. Autti,et al. Clinical and neuroradiological diagnostic aspects of neuronal ceroid lipofuscinoses disorders. , 2001, European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society.
[11] C. Leray,et al. Phospholipid composition in late infantile neuronal ceroid lipofuscinosis , 2000, European journal of clinical investigation.
[12] G. Cohen,et al. Protein complexes activate distinct caspase cascades in death receptor and stress-induced apoptosis. , 2000, Experimental cell research.
[13] W. Brück,et al. Progress in neuropathology of the neuronal ceroid lipofuscinoses. , 1999, Molecular genetics and metabolism.
[14] D. Sleat,et al. Specific alterations in levels of mannose 6-phosphorylated glycoproteins in different neuronal ceroid lipofuscinoses. , 1998, The Biochemical journal.
[15] H. Goebel,et al. The Neuronal Ceroid‐Lipofuscinoses. Recent Advances , 1998, Brain pathology.
[16] D. Palmer,et al. Different patterns of hydrophobic protein storage in different forms of neuronal ceroid lipofuscinosis (NCL, Batten disease). , 1997, Neuropediatrics.
[17] J. Suopanki,et al. Sphingolipid activator proteins (SAPs) in neuronal ceroid lipofuscinoses (NCL). , 1997, Neuropediatrics.
[18] H. Goebel. Topical Review: The Neuronal Ceroid-Lipofuscinoses , 1995 .
[19] M. Baumann,et al. Immunological studies on sphingolipid activator proteins in the neuronal ceroid-lipofuscinoses. , 1995, Gerontology.
[20] H. Goebel. The neuronal ceroid-lipofuscinoses. , 1995, Journal of child neurology.
[21] R. Boustany. Neurology of the neuronal ceroid-lipofuscinoses: late infantile and juvenile types. , 1992, American journal of medical genetics.
[22] T. Autti,et al. Comparison of the clinical courses in patients with juvenile neuronal ceroid lipofuscinosis receiving antioxidant treatment and those without antioxidant treatment. , 1989, Advances in experimental medicine and biology.
[23] J. Alroy,et al. Clinical classification of neuronal ceroid-lipofuscinosis subtypes. , 1988, American journal of medical genetics. Supplement.